OTCPK:CLPB.Y

Stock Analysis Report

Executive Summary

Coloplast A/S develops and markets intimate healthcare products and services worldwide.

Snowflake

Fundamentals

Established dividend payer with adequate balance sheet.


Similar Companies

Share Price & News

How has Coloplast's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.1%

OTCPK:CLPB.Y

0.8%

US Medical Equipment

1.1%

US Market


1 Year Return

12.8%

OTCPK:CLPB.Y

9.6%

US Medical Equipment

2.1%

US Market

CLPB.Y outperformed the Medical Equipment industry which returned 9.1% over the past year.

CLPB.Y outperformed the Market in United States of America which returned 2% over the past year.


Share holder returns

CLPB.YIndustryMarket
7 Day1.1%0.8%1.1%
30 Day-5.7%0.2%3.7%
90 Day0.7%2.7%2.3%
1 Year14.5%12.8%10.5%9.6%4.4%2.1%
3 Year59.5%52.0%69.5%64.3%47.0%37.4%
5 Year47.4%36.9%132.5%105.9%61.6%43.8%

Price Volatility Vs. Market

How volatile is Coloplast's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Coloplast undervalued based on future cash flows and its price relative to the stock market?

40.47x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Coloplast's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Coloplast's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Coloplast is good value based on earnings compared to the US Medical Equipment industry average.

Coloplast is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Coloplast is poor value based on expected growth next year.


Price Based on Value of Assets

Coloplast is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Coloplast expected to perform in the next 1 to 3 years based on estimates from 17 analysts?

9.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Coloplast's revenue is expected to grow by 8.1% yearly, however this is not considered high growth (20% yearly).

Coloplast's earnings are expected to grow by 9.8% yearly, however this is not considered high growth (20% yearly).

Coloplast's revenue growth is expected to exceed the United States of America market average.

Coloplast's earnings growth is positive but not above the United States of America market average.

Coloplast's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Coloplast is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).


Next Steps

Past Performance

How has Coloplast performed over the past 5 years?

16.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Coloplast's year on year earnings growth rate has been positive over the past 5 years.

Coloplast's 1-year earnings growth is less than its 5-year average (7.9% vs 16.1%)

Coloplast's earnings growth has not exceeded the US Medical Equipment industry average in the past year (7.9% vs 28.9%).


Return on Equity

Coloplast made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).


Return on Assets

Coloplast used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Coloplast's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Coloplast's financial position?


Financial Position Analysis

Coloplast is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Coloplast's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Coloplast's level of debt (47.8%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (2.8% vs 47.8% today).

Debt is well covered by operating cash flow (146.5%, greater than 20% of total debt).

Coloplast earns more interest than it pays, coverage of interest payments is not a concern.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 2.3x debt.


Next Steps

Dividend

What is Coloplast's current dividend yield, its reliability and sustainability?

2.36%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Coloplast's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.45%).

Coloplast's dividend is below the markets top 25% of dividend payers in United States of America (3.67%).

Dividends per share have been stable in the past 10 years.

Dividends per share have increased over the past 10 years.


Current Payout to Shareholders

Dividends paid are covered by earnings (1.8x coverage).


Future Payout to Shareholders

Dividends after 3 years are expected to be covered by earnings (1.2x coverage).


Next Steps

Management

What is the CEO of Coloplast's salary, the management and board of directors tenure and is there insider trading?

5.2yrs

Average management tenure


CEO

Kristian Villumsen (49yo)

0.8yrs

Tenure

ø10,400,000

Compensation

Mr. Kristian Villumsen has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an Executive Vice President of Chronic Care at Coloplast A/S since July  ...


CEO Compensation Analysis

Kristian's remuneration is lower than average for companies of similar size in United States of America.

Kristian's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

5.2yrs

Average Tenure

48.5yo

Average Age

The average tenure for the Coloplast management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

2.8yrs

Average Tenure

56yo

Average Age

The average tenure for the Coloplast board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Allan Rasmussen (52yo)

    Executive Vice President of Global Operations

    • Tenure: 5.2yrs
    • Compensation: ø8.40m
  • Nicolai Andersen

    Senior Vice President of Wound Care

    • Tenure: 0yrs
  • Kristian Villumsen (49yo)

    President & CEO

    • Tenure: 0.8yrs
    • Compensation: ø10.40m
  • Anders Lonning-Skovgaard (47yo)

    Executive VP & CFO

    • Tenure: 5.2yrs
    • Compensation: ø8.60m
  • Alain Morvan

    Senior Vice President of Sales Europe

    • Tenure: 7.4yrs
  • Oliver Johansen (48yo)

    Senior Vice President of Global R&D

    • Tenure: 6.8yrs
  • Paul Marcun

    Executive Vice President of Chronic Care

    • Tenure: 0yrs
  • Ellen Bjurgert

    Vice President of Investor Relations

    • Tenure: 2.9yrs
  • Manu Varma

    Senior Vice President of Chronic Care - North America

    • Tenure: 1.4yrs
  • Lina Danstrup

    Senior Media Relations Manager of Corporate Communications

    • Tenure: 0yrs

Board Members

  • Carsten Hellmann (55yo)

    Independent Director

    • Tenure: 1.8yrs
  • Jørgen Tang-Jensen (63yo)

    Independent Director

    • Tenure: 11.8yrs
  • Lars Rasmussen (60yo)

    Chairman of the Board

    • Tenure: 0.8yrs
    • Compensation: ø19.80m
  • Niels Louis-Hansen (72yo)

    Deputy Chairman

    • Tenure: 0yrs
    • Compensation: ø1.00m
  • Thomas Barfod (49yo)

    Senior Controller & Director

    • Tenure: 12.8yrs
  • Jette Nygaard-Andersen (51yo)

    Independent Director

    • Tenure: 3.8yrs
  • Birgitte Nielsen (56yo)

    Independent Director

    • Tenure: 3.8yrs
  • Nikolaj Gundersen (50yo)

    Director

    • Tenure: 1.7yrs
  • Roland Pedersen (57yo)

    Director

    • Tenure: 1.7yrs

Company Information

Coloplast A/S's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Coloplast A/S
  • Ticker: CLPB.Y
  • Exchange: OTCPK
  • Founded: 1954
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: ø166.516b
  • Listing Market Cap: ø24.524b
  • Shares outstanding: 212.12m
  • Website: https://www.coloplast.com

Number of Employees


Location

  • Coloplast A/S
  • Holtedam 1-3
  • Humlebæk
  • 3050
  • Denmark

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CLPB.FOTCPK (Pink Sheets LLC)YesClass B SharesUSUSDMar 1993
COLO BCPSE (OMX Nordic Exchange Copenhagen)YesClass B SharesDKDKKMar 1993
CBHDDB (Deutsche Boerse AG)YesClass B SharesDEEURMar 1993
COLOBCBATS-CHIXE (BATS 'Chi-X Europe')YesClass B SharesGBDKKMar 1993
0QBOLSE (London Stock Exchange)YesClass B SharesGBDKKMar 1993
COLOBSWX (SIX Swiss Exchange)YesClass B SharesCHCHFMar 1993
COLOWBAG (Wiener Boerse AG)YesClass B SharesATEURMar 1993
0QBO NBMV (Bolsa Mexicana de Valores)YesClass B SharesMXMXNMar 1993
CLPB.YOTCPK (Pink Sheets LLC)UNSPONSORD ADRUSUSDNov 2010

Biography

Coloplast A/S develops and markets intimate healthcare products and services worldwide. The company operates through three segments: Chronic Care, Interventional Urology, and Wound & Skin Care. It provides ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/17 00:20
End of Day Share Price2019/09/16 00:00
Earnings2019/06/30
Annual Earnings2018/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.